Genetic Analysis AS, a science-based diagnostic company, (GEAN) Fair Value & Analysis
Healthcare · SE · Market cap 46.0M NOK
Fair value as of: Jun 24, 2026
Analysis
Genetic Analysis AS, a science-based diagnostic company, (GEAN) currently trades at kr 0.6500, while our model-based Fair Value estimate is kr 1.18 — implying the stock looks roughly 81.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test that detects and characterizes dysbiosis; GA-map Discovery, a microbiome research assay; GA-map Sample Collection Kit for the collection, transport, and storage of fecal specimens for nucleic acid analysis; GA-map IBD Precision Dx, a biomarker for inflammatory bowel disease; and GA-map COVID-19 Fecal Test, a qualitative real time standardized PCR test for the detection of the 2019 novel coronavirus RNA in stool samples. It is also involved in the operation of service laboratory where customers can send samples for microbiome profiling analysis; and provision of bioinformatic analysis and cu…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Genetic Analysis AS, a science-based diagnostic company, (GEAN) undervalued?
What is the fair value of GEAN?
What is the quality score of GEAN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.